AbbVie presented new data at the 2026 ASCO Annual Meeting showcasing its oncology pipeline targeting solid tumors and blood cancers. Key findings include promising results from antibody-drug conjugates (ADCs) and T-cell engagers in cancers like metastatic prostate, small cell lung, ovarian, and multiple myeloma. These therapies showed significant response rates and manageable safety profiles in early trials, highlighting AbbVie's innovative approach to cancer treatment. Further clinical data and studies will continue to evaluate these investigational medicines' potential.
AbbVie announced final Phase 3 results from the CLL14 trial showing that a fixed-duration venetoclax plus obinutuzumab treatment significantly improves progression-free survival (PFS) in previously untreated chronic lymphocytic leukemia (CLL) patient...
AbbVie shares have risen over 53% in 2024 driven by strong sales of immunology drugs Skyrizi and Rinvoq, which are offsetting Humira's decline faster than expected. However, the company faces challenges with a negative shareholders’ equity of -$6.6 b...
Healthcare ETFs provide a blend of defensive stability and growth potential by covering broad healthcare sectors and specialized themes like biotechnology, pharmaceuticals, and weight-loss treatments. Aging populations and rising healthcare demand su...
Verizon, Chevron, and AbbVie have all raised their dividends in 2026, appealing to retirees and income-focused investors seeking reliable payouts amid market volatility. Verizon offers a high yield of around 6% with strong cash flow and recent growth...
AbbVie received a Complete Response Letter from the FDA regarding its application for TrenibotE, a fast-acting botulinum neurotoxin serotype E for treating moderate to severe glabellar lines. The FDA's concerns were limited to manufacturing process d...
